While available in only a few countries, home therapy is a possible strategy for the treatment of alpha-1 antitrypsin deficiency. We want to describe our experience in the management of human alpha-1 antitrypsin using home care intravenous augmentation therapy during this emergency period caused by SARS-CoV2 infection. We assessed the safety of the home treatment and the quality of life of patients enrolled in the program.
Keywords: CoV-2; QOL score; SARS; alpha-1 antitrypsin (A1AT); augmentation therapy; home therapy.
Copyright © 2021 Annunziata, Lanza, Coppola, Andreozzi, Spinelli and Fiorentino.